For research use only. Not for therapeutic Use.
Leelamine hydrochloride is a tricyclic diterpene molecule that is extracted from the bark of pine trees[1]. Leelamine hydrochloride is a cannabinoid receptor type 1 (CB1) agonist and a inhibitor of SREBP1-regulated fatty acid/lipid synthesis in prostate cancer cells that is not affected by androgen receptor status. Leelamine hydrochloride suppresses transcriptional activity of androgen receptor, which is known to regulate fatty acid synthesis[2,3].
Catalog Number | R056853 |
CAS Number | 16496-99-4 |
Synonyms | [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine;hydrochloride |
Molecular Formula | C20H32ClN |
Purity | ≥95% |
InChI | InChI=1S/C20H31N.ClH/c1-14(2)15-6-8-17-16(12-15)7-9-18-19(3,13-21)10-5-11-20(17,18)4;/h6,8,12,14,18H,5,7,9-11,13,21H2,1-4H3;1H/t18-,19-,20+;/m0./s1 |
InChIKey | CVPQLGCAWUAYPF-WFBUOHSLSA-N |
SMILES | CC(C)C1=CC2=C(C=C1)C3(CCCC(C3CC2)(C)CN)C.Cl |
Reference | [1]. Kuzu OF, et al. Leelamine mediates cancer cell death through inhibition of intracellular cholesterol transport. Mol Cancer Ther. 2014 Jul;13(7):1690-703. [2]. A.O. Ibegbu, et al. Therapeutic Potentials and uses of Cannabinoid Agonists in Health and Disease Conditions. British Journal of Pharmacology and Toxicology 3(2): 76-88, 2012 [3]. Singh KB, et al. Leelamine is a Novel Lipogenesis Inhibitor in Prostate Cancer Cells In Vitro and In Vivo. Mol Cancer Ther. 2019 Aug 8. |